What the label lists and what reports show
Triamcinolone side effects
Triamcinolone's FDA label lists its adverse reactions in its own words. FAERS holds 31,591 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is pruritus (2,642 reports).
- Generic listed
Check it at the source: the triamcinolone FDA label on DailyMed (effective January 28, 2026, E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC); the FDA FAERS public dashboard.
What does the label list?
From the label: adverse reactionsThe following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
Table 1: Ocular Adverse Reactions Reported in ≥ 2% of Patients and Non-ocular Adverse Reactions Reported in ≥ 5% of Patients
This table is printed in the Xipere label published by Bausch & Lomb Incorporated of October 8, 2025; the label quoted above does not print one.
| Adverse Reaction | XIPERE ® (N = 96) n (%) | Control (N = 64) n (%) |
|---|---|---|
| Increased intraocular pressure, non-acute a, b | 13 (14%) | 9 (14%) |
| Eye pain, non-acute b | 11 (12%) | 0 |
| Cataract c | 7 (7%) | 4 (6%) |
| Increased intraocular pressure, acute a, d | 6 (6%) | 0 |
| Vitreous detachment | 5 (5%) | 1 (2%) |
| Injection site pain | 4 (4%) | 2 (3%) |
| Conjunctival haemorrhage | 4 (4%) | 2 (3%) |
| Visual acuity reduced | 4 (4%) | 1 (2%) |
| Dry eye | 3 (3%) | 1 (2%) |
| Eye pain, acute d | 3 (3%) | 0 |
| Photophobia | 3 (3%) | 0 |
| Vitreous floaters | 3 (3%) | 0 |
| Uveitis | 2 (2%) | 7 (11%) |
| Conjunctival hyperaemia | 2 (2%) | 2 (3%) |
| Punctate keratitis | 2 (2%) | 1 (2%) |
| Conjunctival oedema | 2 (2%) | 0 |
| Meibomianitis | 2 (2%) | 0 |
| Anterior capsule contraction | 2 (2%) | 0 |
| Chalazion | 2 (2%) | 0 |
| Eye irritation | 2 (2%) | 0 |
| Eye pruritus | 2 (2%) | 0 |
| Eyelid ptosis | 2 (2%) | 0 |
| Photopsia | 2 (2%) | 0 |
| Vision blurred | 2 (2%) | 0 |
| Headache | 5 (5%) | 2 (3%) |
Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.
Source: FDA drug label, E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC, effective January 28, 2026 (SPL set 92a1ded0-8e1a-4994-9c8a-89e84fc85c94), via openFDA; the full label on DailyMed
What do FAERS reports show?
31,591 reports list triamcinolone among the medicines taken, each a report of something that happened, not proof the medicine caused it; 3,076 are coded as a death and 6,572 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Of the 20 reactions below, 2 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.
Reports received each year
The 25 most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms
What next?
- Triamcinolone: the full record
- label, generics, price, shortages, recalls
- Report a side effect to the FDA
- MedWatch
- Side effects hub
- the most reported medicines and reactions